|
gptkbp:instanceOf
|
gptkb:vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:alsoKnownAs
|
gptkb:Vaxzevria
gptkb:AZD1222
gptkb:Covishield
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Brazil
gptkb:Canada
gptkb:European_Union
gptkb:India
gptkb:South_Korea
gptkb:United_Kingdom
December 2020
many other countries
|
|
gptkbp:category
|
gptkb:AstraZeneca
gptkb:COVID-19_pandemic
Vaccines
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contains
|
SARS-CoV-2 spike protein gene
replication-deficient chimpanzee adenovirus vector
|
|
gptkbp:developedBy
|
gptkb:University_of_Oxford
gptkb:AstraZeneca
|
|
gptkbp:distributedBy
|
gptkb:COVAX
|
|
gptkbp:dosingSchedule
|
two doses
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
~70%
|
|
gptkbp:emergencyUseListingBy
|
gptkb:World_Health_Organization
|
|
gptkbp:intervalBetweenDoses
|
4–12 weeks
|
|
gptkbp:manufacturer
|
gptkb:SK_Bioscience
gptkb:Wockhardt
gptkb:Serum_Institute_of_India
gptkb:Catalent
gptkb:Fiocruz
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
rare blood clotting events
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
gptkb:viral_vector_vaccine
|
|
gptkbp:bfsParent
|
gptkb:UK_government_COVID-19_response
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oxford-AstraZeneca
|